Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# IVEAcare | Advancing the Future of Vagus Nerve Stimulation

IVEAcare | Advancing the Future of Vagus Nerve Stimulation

## Sitemaps

- [XML Sitemap](https://iveacare.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors IveaCare Secures](https://iveacare.com/iveacare-launches-with-27-5-million-in-series-a-funding-from-leading-medtech-investors-iveacare-secures/) - MINNEAPOLIS, April 22, 2024 — iVEAcare, a privately held, development stage medical device company, announced the close of a $27.5 million Series A financing.

## Pages

- [Home](https://iveacare.com/) - Advancing the Future of Vagus Nerve Stimulation Driving innovation in epilepsy care Contact iVEAcare is a medical technology company dedicated to advancing the science and clinical application of vagus nerve stimulation (VNS) for individuals living with epilepsy. We are focused on developing innovative neuromodulation technologies with the potential to improve the lives of patients and
- [Contact](https://iveacare.com/contact/) - Contact Us USA Branch Australian Branch Our Address: iVEAcare, Inc 1905 County Road C West, Roseville,MN 55113 Phone: +1 (651) 728-4832 First Name Last Name Email Company Name Message Send Our Address: iVEAcare Australia Pty Ltd Parkline Place, Level 25, 252 Pitt Street, Sydney, NSW 2000, Australia Phone: +1 (651) 728-4832 First Name Last Name Email Company
- [Product Security](https://iveacare.com/product-security/) - Product Security Product SecurityThe cybersecurity landscape is continually evolving, and iVEAcare continuously assesses new vulnerabilities that could impact the safety, effectiveness, or intended use of our neuromodulation products.Questions or concerns about product security?Patient question contact: +1 (651) 728-4832 or your physician.Security question email: info@iveacare.comCoordinated Vulnerability Disclosure ProcessIf you believe you have identified a potential security
- [Accessibility](https://iveacare.com/accessibility/) - Accessibility Accessibility NoticeOur CommitmentiVEAcare, Inc. is committed to making our website and digital content accessible to all individuals, including those with disabilities.Our StandardsWe strive to meet the Web Content Accessibility Guidelines (WCAG) 2.1 at the AA level. To support this, we:Include accessibility in our web development process.Provide text alternatives for non-text content.Ensure sufficient color contrast.Design
- [Old home](https://iveacare.com/old-home/) - We Develop Novel Therapies to Address Unmet Needs At IVEAcare we are focused on developing and commercializing next generation neuromodulation technology platforms to treat patients suffering from chronic diseases. Translating Complexity into Clarity By synthesizing multi-modal data streams, our platform is designed to cut through the noise of neurological variability. We provide clinicians with actionable
- [News](https://iveacare.com/news/) - News April 22, 2024 iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors IveaCare Secures MINNEAPOLIS, April 22, 2024 — iVEAcare, a privately held, development stage medical device company, announced the close of a $27.5 million Series A financing. Read More
- [About](https://iveacare.com/about/) - About About Us IVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations. Leadership We are serial entrepreneurs, engineers, and investors with extensive experience in implantable medical devices who have successfully developed and commercialized many new therapies in the bioelectronics space. We partner with leading physicians to improve the standard
- [Privacy Policy](https://iveacare.com/privacy-policy/) - Privacy Policy Privacy PolicyEffective Date: March 17, 2026IntroductioniVEAcare, Inc. (“iVEAcare,” “we,” “our,” or “us”) respects your privacy and is committed to protecting the personal information you share with us. This Privacy Policy describes how we collect, use, disclose, and safeguard your information when you visit our website at www.iveacare.com or interact with us through other
- [clinical study detail](https://iveacare.com/clinical-study-detail/) - Clinical Study Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy iVEAcare is undertaking a clinical study in Australia and New Zealand in participants with a history of Epilepsy, with focal (partial) onset seizures, or generalised seizures, which have been shown to be drug resistant. Drug-resistant epilepsy is defined as the
- [Clinical](https://iveacare.com/clinical/) - Clinical Study Participants enter your passcode to learn more about the study. Access Code Invalid access code. Please try again. Submit

## Categories

- [Uncategorized](https://iveacare.com/category/uncategorized/)